Siogen Biotech and Veeda Clinical Research have agreed to jointly develop a new nanoparticle formulation of Doxorubicin for the treatment of cancer. Under the terms of the agreement, Siogen will use its patented Siosomes® silane-based nanoparticle drug delivery and targeting technology to encapsulate Doxorubicin, an established drug used in chemotherapy for the treatment of leukemias, lymphomas and other cancers. Veeda will conduct Phase I/II clinical trials of the formulation.
Siosomes® are nanoparticle vesicles consisting of two or more concentric, organo-silicon phopholipid bilayer compounds based on the Silane (SiH4) general structure. These can be manufactured in different sizes, dependent on use and requirements, ranging from 40nm - 1500nm in size.
Encapsulation of Doxorubicin in Siosomes® is designed to increase the efficacy of the drug through targeted delivery to the site of disease and to decrease adverse effects by lowering the exposure of the drug to the tissues and cells.
- here's the release